Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 01, 2021

SELL
$49.26 - $74.5 $135,169 - $204,428
-2,744 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$56.91 - $127.53 $156,161 - $349,942
2,744 New
2,744 $202,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $551M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Qcm Cayman, Ltd. Portfolio

Follow Qcm Cayman, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qcm Cayman, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Qcm Cayman, Ltd. with notifications on news.